Literature DB >> 23730045

Oophorectomy in breast cancer-controversies and current status.

Gurpreet Singh1.   

Abstract

The role of oophorectomy in the treatment of breast cancer is known for over 100 years. Ovarian ablation has a relatively large positive effect on both disease-free survival (DFS) and overall survival (OS) in premenopausal women when compared to no adjuvant treatment. Today the standard of care in adjuvant therapy of endocrine responsive tumors in premenopausal women is tamoxifen with or without chemotherapy. The role of oophorectomy /ovarian ablation in current surgical practice is discussed and important issues highlighted in the article.

Entities:  

Keywords:  Breast cancer; Oophorectomy; Ovarian ablation

Year:  2012        PMID： 23730045      PMCID： PMC3397181          DOI： 10.1007/s12262-012-0584-7

Source DB:  PubMed          Journal:  Indian J Surg        ISSN： 0973-9793            Impact factor:   0.656


  9 in total

1.  Oophorectomy for breast cancer: history revisited.

Authors:  Richard R Love; John Philips
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

2.  Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

Authors:  Nancy E Davidson; Anne M O'Neill; Allen M Vukov; C Kent Osborne; Silvana Martino; Douglas R White; Martin D Abeloff
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

Authors: 
Journal:  N Engl J Med       Date:  1988-12-29       Impact factor: 91.245

4.  Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.

Authors:  Asgerdur Sverrisdottir; Hemming Johansson; Ulla Johansson; Jonas Bergh; Samuel Rotstein; Larserik Rutqvist; Tommy Fornander
Journal:  Breast Cancer Res Treat       Date:  2011-05-29       Impact factor: 4.872

Review 5.  American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer.

Authors:  Jennifer J Griggs; Mark R Somerfield; Holly Anderson; N Lynn Henry; Clifford A Hudis; James L Khatcheressian; Ann H Partridge; Ann Alexis Prestrud; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

6.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

7.  Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Authors:  J Cuzick; L Ambroisine; N Davidson; R Jakesz; M Kaufmann; M Regan; R Sainsbury
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321

8.  Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study.

Authors:  J A Söreide; J E Varhaug; H E Fjösne; B Erikstein; A-B Jacobsen; E Skovlund; S Kvinnsland
Journal:  Eur J Surg Oncol       Date:  2002-08       Impact factor: 4.424

9.  Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Authors:  Sandra M Swain; Jong-Hyeon Jeong; Charles E Geyer; Joseph P Costantino; Eduardo R Pajon; Louis Fehrenbacher; James N Atkins; Jonathan Polikoff; Victor G Vogel; John K Erban; Priya Rastogi; Robert B Livingston; Edith A Perez; Eleftherios P Mamounas; Stephanie R Land; Patricia A Ganz; Norman Wolmark
Journal:  N Engl J Med       Date:  2010-06-03       Impact factor: 176.079
  9 in total
  3 in total

1.  Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study.

Authors:  Dwi Ris Andriyanto; Salman Ardi Syamsu; Muhammad Ihwan Kusuma; Joko Hendarto; Nilam Smaradania; Elridho Sampepajung; Asrul Mappiwali; Muhammad Faruk
Journal:  Ann Med Surg (Lond)       Date:  2022-04-11

Review 2.  Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer.

Authors:  Woo-Chan Park
Journal:  J Breast Cancer       Date:  2016-12-23       Impact factor: 3.588

3.  Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer-A Single-Center Analysis.

Authors:  Joana Correia Oliveira; Filipa Costa Sousa; Inês Gante; Margarida Figueiredo Dias
Journal:  Medicina (Kaunas)       Date:  2021-04-16       Impact factor: 2.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.